J.-L. Lee

453 total citations · 1 hit paper
11 papers, 339 citations indexed

About

J.-L. Lee is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, J.-L. Lee has authored 11 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Molecular Biology. Recurrent topics in J.-L. Lee's work include Renal cell carcinoma treatment (5 papers), Renal and related cancers (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). J.-L. Lee is often cited by papers focused on Renal cell carcinoma treatment (5 papers), Renal and related cancers (4 papers) and Pancreatic and Hepatic Oncology Research (3 papers). J.-L. Lee collaborates with scholars based in South Korea, United States and Spain. J.-L. Lee's co-authors include Cheryn Song, Jun Hyuk Hong, Lee Js, Jeong Eun Kim, Bumsik Hong, Hee‐Sung Ahn, Changhee Yoo, T. M. Kim, Yohann Loriot and Jonathan E. Rosenberg and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Japanese Journal of Clinical Oncology.

In The Last Decade

J.-L. Lee

10 papers receiving 332 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma

2023 84 citations Jonathan E. Rosenberg, Thomas Powles et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J.-L. Lee South Korea	8	215	137	129	94	91	11	339
Qi Xia United States	9	216 1.0×	122 0.9×	206 1.6×	82 0.9×	134 1.5×	26	418
Jitka Abrahámová Czechia	10	182 0.8×	147 1.1×	168 1.3×	95 1.0×	91 1.0×	44	406
Guillaume Mouillet France	11	319 1.5×	212 1.5×	146 1.1×	77 0.8×	105 1.2×	33	465
Marco Stellato Italy	10	229 1.1×	206 1.5×	87 0.7×	101 1.1×	82 0.9×	43	408
Hun-Mo Ryoo South Korea	10	112 0.5×	102 0.7×	106 0.8×	40 0.4×	47 0.5×	30	300
Shiven B. Patel United States	12	168 0.8×	276 2.0×	106 0.8×	31 0.3×	41 0.5×	47	420
Tomohiro Funakoshi United States	9	110 0.5×	111 0.8×	96 0.7×	51 0.5×	53 0.6×	11	327
Annalisa Guida Italy	11	246 1.1×	165 1.2×	108 0.8×	61 0.6×	72 0.8×	39	323
J McKendrick Australia	9	180 0.8×	338 2.5×	121 0.9×	81 0.9×	59 0.6×	24	525
Annelies Verbiest Belgium	11	242 1.1×	138 1.0×	177 1.4×	58 0.6×	116 1.3×	32	386

Countries citing papers authored by J.-L. Lee

Since Specialization

Citations

This map shows the geographic impact of J.-L. Lee's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J.-L. Lee with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J.-L. Lee more than expected).

Fields of papers citing papers by J.-L. Lee

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J.-L. Lee. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J.-L. Lee. The network helps show where J.-L. Lee may publish in the future.

Co-authorship network of co-authors of J.-L. Lee

This figure shows the co-authorship network connecting the top 25 collaborators of J.-L. Lee. A scholar is included among the top collaborators of J.-L. Lee based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J.-L. Lee. J.-L. Lee is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Rosenberg, Jonathan E., Thomas Powles, Guru Sonpavde, et al.. (2023). EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma. Annals of Oncology. 34(11). 1047–1054. 84 indexed citations breakdown →

Quinn, David I., Chi‐Fai Ng, Enrique Grande, et al.. (2021). ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups. ESMO Open. 6(3). 100105–100105. 6 indexed citations

Necchi, Andrea, Yves Fradet, Joaquim Bellmunt, et al.. (2019). Three-year follow-up from the phase III KEYNOTE-045 trial: Pembrolizumab (Pembro) versus investigator’s choice (paclitaxel, docetaxel, or vinflunine) in recurrent, advanced urothelial cancer (UC). Annals of Oncology. 30. v366–v367. 9 indexed citations

McDermott, David F., Ulka N. Vaishampayan, Marc Matrana, et al.. (2019). Safety and efficacy of the oral CXCR4 inhibitor X4P-001 + axitinib in advanced renal cell carcinoma patients: An analysis of subgroup responses by prior treatment. Annals of Oncology. 30. v482–v483. 8 indexed citations

Neiman, Victoria, Daniel Keizman, David Sarid, et al.. (2016). Outcome of patients with metastatic chromophobe renal cell carcinoma treated with sunitinib. Annals of Oncology. 27. vi289–vi289.

Lee, J.-L., Jin‐Hee Ahn, Ho Yeong Lim, et al.. (2012). Multicenter phase II study of sunitinib in patients with non-clear cell renal cell carcinoma. Annals of Oncology. 23(8). 2108–2114. 77 indexed citations

Yoo, Changhee, Jeong Eun Kim, J.-L. Lee, et al.. (2010). The Efficacy and Safety of Sunitinib in Korean Patients with Advanced Renal Cell Carcinoma: High Incidence of Toxicity Leads to Frequent Dose Reduction. Japanese Journal of Clinical Oncology. 40(10). 980–985. 80 indexed citations

Kim, Min Kyoung, J.-L. Lee, Hong Song, et al.. (2008). Palliative Chemotherapy Preferences and Factors that Influence Patient Choice in Incurable Advanced Cancer. Japanese Journal of Clinical Oncology. 38(1). 64–70. 10 indexed citations

Jo, Jae‐Cheol, J.-L. Lee, M.-H. Ryu, et al.. (2007). Docetaxel Monotherapy as a Second-line Treatment after Failure of Fluoropyrimidine and Platinum in Advanced Gastric Cancer: Experience of 154 Patients with Prognostic Factor Analysis. Japanese Journal of Clinical Oncology. 37(12). 936–941. 32 indexed citations

10.

Lee, J.-L., et al.. (2005). Efficacy and safety study of docetaxel as salvage chemotherapy in metastatic gastric cancer failing fluoropyrimidine and platinum combination chemotherapy. Journal of Clinical Oncology. 23(16_suppl). 4220–4220. 5 indexed citations

11.

Lee, J.-L.. (2004). A Case of Bone Marrow Necrosis with Thrombotic Thrombocytopenic Purpura as a Manifestation of Occult Colon Cancer. Japanese Journal of Clinical Oncology. 34(8). 476–480. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact